Imatinib sensitizes T-cell lymphocytes from chronic myeloid leukemia patients to FasL-induced cell death: A brief communication

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 154-158

  Legros, Laurence ^a,b   Ebran, Nathalie ^a   Stebe, Emmanuelle ^a   Rousselot, Philippe ^c   Rea, Delphine ^d   Cassuto, Jill Patrice ^b   Mahon, Francois Xavier ^e   Hueber, Anne Odile ^a  

^a CNRS   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

cell death; chronic myeloid leukemia; Fas CD95; imatinib; lymphocyte

Indexed keywords

DEATH RECEPTOR; FAS ANTIGEN; IMATINIB;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SEPARATION; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 84856888577     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318243f238     Document Type: Article

References (13)

1. Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004;18:1332-1339. (Pubitemid 39136740)
2. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner. Blood. 2005;105:2473-2479. (Pubitemid 40387048)
3. Gao H, Lee BN, Talpaz M, et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia. 2005;19:1905-1911. (Pubitemid 41553998)
4. Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: Apoptosis revisited. Cell. 2007;129:447-450. (Pubitemid 46660984)
5. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180-192.
6. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2011;11:1029-1035.
7. Steegmann JL, Moreno G, Alaez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica. 2003;88:762-768. (Pubitemid 36890110)
8. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
9. Boissel N, Rousselot P, Raffoux E, et al. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J Leukoc Biol. 2006;79:747-756. (Pubitemid 44835607)
10. Tybulewicz VL, Crawford CE, Jackson PK, et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991;65:1153-1163. (Pubitemid 121001329)
11. Agosti V, Corbacioglu S, Ehlers I, et al. Critical role for Kitmediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med. 2004;199:867-878. (Pubitemid 38375206)
12. Waskow C, Paul S, Haller C, et al. Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity. 2002;17:277-288. (Pubitemid 35279549)
13. Sakata S, Sakamaki K,Watanabe K, et al. Involvement of death receptor Fas in germ cell degeneration in gonads of Kit-deficient Wv/Wv mutant mice. Cell Death Differ. 2003;10:676-686. (Pubitemid 36675729)